461 – 470 of 556
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2005
-
Mark
Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers
(
- Contribution to journal › Article
-
Mark
ERK phosphorylation is linked to VEGFR2 expression and Ets-2 phosphorylation in breast cancer and is associated with tamoxifen treatment resistance and small tumours with good prognosis
(
- Contribution to journal › Article
-
Mark
High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: Implications for breast and ovarian cancer risk.
(
- Contribution to journal › Article
-
Mark
Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
(
- Contribution to journal › Article
-
Mark
ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells.
(
- Contribution to journal › Article
-
Mark
Inverse vs. forward breast IMRT planning
(
- Contribution to journal › Article
-
Mark
Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study
(
- Contribution to journal › Article
-
Mark
High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells.
(
- Contribution to journal › Article
-
Mark
Estrogen receptor alpha and beta in breast cancer - gene expression profiles and clinical implications
2005)(
- Thesis › Doctoral thesis (compilation)
-
Mark
TISSUE MICROARRAY PERSPECTIVES ON CYCLIN D1 IN BREAST CANCER: Progression, prognosis and prediction
2005)(
- Thesis › Doctoral thesis (compilation)